obicetrapib experimental cetp inhibitor intended treat dyslipidemia clinical trial addon statins decreased ldlc concentration p primary trial outcome compared placebo obicetrapib treatment also significantly p decreased apolipoprotein b nonhighdensity lipoprotein cholesterol nonhdlc concentration significantly p increased hdlc concentration secondary trial phase iii httpsenwikipediaorgwikiobicetrapib